4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nurix Therapeutics, Inc. (NRIX) operates in the Biotechnology industry and is headquartered in Brisbane, United States with about 317 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-11-30, NRIX reported $84M in revenue and ($264M) in net income.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Interactive charts & full statements → Open the NRIX valuation workbench →
| Income statement | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Total Revenue | $84M | $54M | $77M | $39M |
| Operating Income (EBIT) | ($286M) | ($213M) | ($155M) | ($184M) |
| Net Income | ($264M) | ($194M) | ($144M) | ($180M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 |
|---|---|---|---|---|---|---|
| Total Revenue | $9M | $6M | $14M | $8M | $44M | — |
| Operating Income (EBIT) | ($94M) | ($92M) | ($83M) | ($91M) | ($48M) | — |
| Net Income | ($90M) | ($87M) | ($78M) | ($86M) | ($44M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 | 2021-11-30 |
|---|---|---|---|---|---|
| Total Assets | $688M | $669M | $356M | $417M | — |
| Total Liabilities | $149M | $142M | $155M | $113M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NRIX viewer.
About TickerBase · Data methodology & sources